CN1205333A - 非离子维生素e衍生物、其制法和用其制备的聚合两亲水泡液 - Google Patents
非离子维生素e衍生物、其制法和用其制备的聚合两亲水泡液 Download PDFInfo
- Publication number
- CN1205333A CN1205333A CN97119987A CN97119987A CN1205333A CN 1205333 A CN1205333 A CN 1205333A CN 97119987 A CN97119987 A CN 97119987A CN 97119987 A CN97119987 A CN 97119987A CN 1205333 A CN1205333 A CN 1205333A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- polyethoxylated
- nonionic
- derivative
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003712 vitamin E derivatives Chemical class 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title claims abstract description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 96
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 46
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 46
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 46
- 239000011709 vitamin E Substances 0.000 claims abstract description 46
- 229940046009 vitamin E Drugs 0.000 claims abstract description 46
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 5
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 238000006116 polymerization reaction Methods 0.000 claims description 12
- 239000012530 fluid Substances 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 239000000010 aprotic solvent Substances 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 claims description 4
- 239000011627 DL-alpha-tocopherol Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate group Chemical group C(C(=C)C)(=O)[O-] CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 16
- 230000003078 antioxidant effect Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 11
- 229940089960 chloroacetate Drugs 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000004094 surface-active agent Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 150000003904 phospholipids Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- KDPAWGWELVVRCH-UHFFFAOYSA-M bromoacetate Chemical compound [O-]C(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-M 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 125000001165 hydrophobic group Chemical group 0.000 description 4
- 235000020778 linoleic acid Nutrition 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 4
- 230000001766 physiological effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- NOTFZGFABLVTIG-UHFFFAOYSA-N Cyclohexylethyl acetate Chemical compound CC(=O)OCCC1CCCCC1 NOTFZGFABLVTIG-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 239000003012 bilayer membrane Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PNVPNXKRAUBJGW-UHFFFAOYSA-N (2-chloroacetyl) 2-chloroacetate Chemical compound ClCC(=O)OC(=O)CCl PNVPNXKRAUBJGW-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- WIYVVIUBKNTNKG-UHFFFAOYSA-N 6,7-dimethoxy-3,4-dihydronaphthalene-2-carboxylic acid Chemical compound C1CC(C(O)=O)=CC2=C1C=C(OC)C(OC)=C2 WIYVVIUBKNTNKG-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 238000007348 radical reaction Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- PTZRYAAOQPNAKU-UHFFFAOYSA-N 2-[(1-carboxy-3-cyanobutyl)diazenyl]-4-cyanopentanoic acid Chemical compound N#CC(C)CC(C(O)=O)N=NC(C(O)=O)CC(C)C#N PTZRYAAOQPNAKU-UHFFFAOYSA-N 0.000 description 1
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical compound ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000006265 aqueous foam Substances 0.000 description 1
- 239000003876 biosurfactant Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical class C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 150000002313 glycerolipids Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- KNMNNEPMKDJBDW-UHFFFAOYSA-N n-[2-(3,4-dimethoxyphenyl)ethyl]-1-(2,6-dimethylphenoxy)propan-2-amine;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCNC(C)COC1=C(C)C=CC=C1C KNMNNEPMKDJBDW-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000001132 ultrasonic dispersion Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
- C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F220/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
- C08F220/365—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate containing further carboxylic moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
公开了右式(Ⅰ)所代表的非离子维生素E或多乙氧基化的维生素E衍生物及其制备方法,以及用其制得的聚合两亲水泡液:其中,n为0—30的整数,包括端值;A为-CH2-CH(CH3)-或-CH=C(CH3)-;B为位于5-,7-或8-位的-CH3;m为1,2,或3;和R为上式(Ⅱ)所代表的丙烯酸酯或甲基丙烯酸酯衍生物残基:其中,R1为H或CH3。
Description
本发明涉及能形成聚合两亲水泡液的非离子维生素E衍生物及其制备方法。具体地说,本发明涉及能形成聚合两亲水泡液的非离子维素素E或多乙氧基化的维生素E衍生物及其制备方法,和用其制备聚合的两亲水泡液,该水泡液显示了优异的热力学稳定性,生物体相容性及生理活性(如抗氧化作用)。
各种油性物质如甘油三酯,脂肪酸酯或石蜡已经广地在化妆品中用作润肤剂和外用皮肤软膏,以阻止水汽从皮肤表面蒸发。然而,含有这些油性物质的化妆品或皮肤软膏还需要用表面活性剂,以补偿其与作为化妆品和皮肤软膏基本成份的水或水溶性成份之间很差的相容性。
表面活性剂是一种两亲分子,既有亲液基团,又有憎液基团,也就是说,它是由一条含有极性基团的长的烷基链组成。而且,表面活性剂在溶液中显示有表面活性,当表面活性剂溶质在溶液总体中的浓度超过一临界值,即所谓的临界胶束浓度时,形成被称为胶束的分子或离子聚集体。胶束可以是球形的,圆柱形的或盘状的,并能使水溶液中不溶于水的物质溶解度增大。
另外,有许多天然的两亲的生物化合物如甘油脂,蛋白质,磷脂,皂角苷和胆质醇,这些化合物因其来源和表面活性而被称为“生物表面活性剂”。由于其具有表面活性,这些生物物质能够很容易地溶解于水和其它水溶液中,从而有效地发挥其生理活性,并且很容易吸收其它物质。特别是磷脂是膜脂的组成部分,还能容易地形成脂质体,因为磷脂含有由两条脂肪链组成的憎水基团;磷脂也具有优异的安全防护和保湿活性,因为它们是生物细胞的组成部分。然而,由于磷脂分子中含有双键,其很容易被氧化成过氧化物,从而引起细胞损伤,结果促进了衰老。
因此,就开发新型的能形成与由磷脂形成的脂质体相似的水泡液的物质进行了深入的研究和讨论。
由于只有当表面活性剂有两条烷基链和相平衡的憎水、亲水活性时,它才具有形成水泡液的能力,对表面活性剂的研究集中于开发合成的两亲化合物。
杰·埃姆·戈比基(J.M.Gebicki)和埃姆·黑克斯(M.Hicks)于1975年第一次报道了用合成的两亲物质形成的水泡液形成的双层膜结构。这种双层膜结构是通过在水溶性缓冲液中摇振一薄层油酸和亚油酸而形成的。然而,这种封闭的双层膜结构只在pH6~8时稳定,而且不能用例如离心方法浓缩。
之后,孔尼泰克(Kunitake)等人报道了用超声波方法分散二烷基二甲基铵和双-十六烷基磷酸酯而形成的水泡液,这样得到的水泡液在全部pH范围都是稳定的。然而,这些合成的表面活性剂水泡液热力学稳定性差,长期存放很容易凝集并沉淀出来,这就限制了合成表面活性剂水泡液的应用。
近来,有人提出用水泡液聚合来改善合成的水泡液的稳定性,除此之外,也有报道了“聚合肥皂”,它是聚合的含有一条烷基链的两亲分子。
因此,本发明人作了深入的研究以开发新型的聚合两亲水泡液。该研究基于这样的事实,即维生素E或多乙氧基化的维生素E衍生物具有优异的生物体相容性、表面活性、抗氧化作用如保护皮肤或头发不受氧化或紫外线的作用、消炎作用以及作为形成水泡液的憎水基团而具有足够的憎水和定向特性,结果,本发明人提出了通过把季氮阳离子基团引入维生素E或多乙氧基化的维生素E而得到的阳离子型维生素E或多乙氧基维生素E衍生物,以及用其制成的聚合两亲水泡液。正如所期望的那样,所提出的阳离子维生素E或多乙氧基化的维生素E具有优异的形成水泡液的能力。但是,由于其阳离子特性,它们与生物体中的阴离子或两亲成份的相容性很差。基于这一缺点,本发明人又提出通过把丙烯酸酯、甲基丙烯酸酯或丁烯酸酯衍生物引入维生素E或多乙氧基化的维生素E,而得到非离子的维生素E或多乙氧基化的维生素E衍生物,以及用其制成的聚合两亲水泡液,但是,这种非离子衍生物缺乏能阻止生理活性物质氧化的抗氧化作用。
在这种情况下,本发明人进行了研究,以提供解决上述问题的办法。结果,他们发现,通过控制反应温度和把含有氨基的烯丙基衍生物引入维生素E或多乙氧基化的维生素E衍生物时所用的反应物的量,可以得到非离子的聚合两亲水泡液。他们证实,所提出的非离子的水泡液表现了优异的热力学稳定性、生物体相容性和生理活性如抗氧化作用。
本发明的一个目的是提供下式(Ⅰ)所代表的非离子维生素E或多乙氧化基的维生素E衍生物:其中,
n是0-30的整数,包括端值;
A是-CH2-CH(CH3)-或 ;
B是位于5-,7-,或8-位的甲基
m为1,2,或3;和
R1为H或CH3。
本发明的另一个目的是提供一种制备式(Ⅰ)所代表的非离子维生素E或多乙氧基化的维生素E衍生物的方法。
n,A,B,m和R的定义如上;而
P表示由10-1,000的整数所代表折聚合度。
通过以下的详细的描述,本发明的这些和其它目的及特征对于本领域的技术人员来说将是显而易见的。
以下将对本发明作更详细的描述。
这里所用的术语“水泡”指由合成的表面活性剂形成的小孢子,其意义与磷脂所形成的脂质体意义相同,而这里所用的术语“聚合水泡”指聚合所说的合成表面活性剂所形成的水泡。
本发明的制备非离子的维生素E或多乙氧基化的维生素E衍生物的方法包括下列步骤:
B,n和m定义如上;
A为-CH2-CH(CH3)-或 ;和
X为F,Cl,Br和I。
(b)使步骤(a)中式(Ⅴ)的维生素E卤代乙酸酯或多乙氧基化的维生素E卤代乙酸酯衍生物与下式(Ⅵ)所代表的丙烯酸酯或甲基丙烯酸酯衍生物,按1∶1.5或更高的摩尔比,在非质子性溶剂中,于100-200℃的温度下反应:其中,
R1的定义如上。
上述方法中所用的维生素E可含有合成或天然的例如从植物种子中提取的维生素E。合成的维生素E可包括但不限于:dι-α-维生素E,dι-β-维生素E,dι-γ-维生素E和dι-δ-维生素E。
更进一步地说,其中含有1-30摩尔的环氧乙烷的多乙氧基化的维生素E衍生物考虑到其聚合两亲水泡液在水中的溶解性能、流动性、以及有规律排列的结晶性而被优选使用。
优选地,使化合物(Ⅴ)与化合物(Ⅵ)以1∶1.5或更大的摩尔比反应,过量的化合物(Ⅵ)将加速步骤(b)中亲核取代反应。而且,为了使这种取代更容易进行,反应优选在非质子性溶剂中进行。非质子性溶剂的例子可包括但不限于:二噁烷、二甲基甲酰胺(DMF)和四氢呋喃(THF)。
而且,重要的是让步骤(b)的反应在100-200℃的温度下进行,优选在120-170℃的温度下反应。
式(Ⅲ)的聚合两亲水泡液可通过把本发明的非离子维生素E衍生物分散,或者优选用超声波处理,然后使非离子维生素E衍生物聚合(假如优选的话)而得到。
非离子维生素E衍生物的聚合可用自由基引发剂在50-80℃的温度下进行或者在紫外线照射下进行。
该聚合中所用的自由基引发剂可包括但不限于:过硫酸钾(K2S2O8)、过氧化氢(H2O2)、偶氮异丁腈(AIBN)和偶氮双(4-氰戊酸)。
上述方法提供的化合物(Ⅰ)具有把维生素E或多乙氧基化的维生素E衍生物的憎水基团与用于聚合的叔氨基组合起来的结构。由于这种结构,通过超声波分散、圆筒注射等方法,化合物(Ⅰ)能形成水泡液。特别是,由于化合物(Ⅰ)具有用于聚合的双键,它能很容易地用自由基聚合法或紫外线照射法聚合,而且,经过聚合的水泡液比水泡单体更稳定。
当把本发明的聚合两亲水泡液掺入化妆品或药物组合物中时,它们显示了与其中所含的水溶性活性成分良好的相容性,从而由于它们的表面活性和形成水泡液的能力,通过增加它们与皮肤的亲和性,改善了这种成分的活性。另外,本发明的聚合两亲水泡液也表现了比维生素E更好的抗氧化作用和保湿作用。该改善的抗氧化作用能有效地阻止生理活性物质和生物膜的氧化,因此能延缓皮肤衰老,而且,改善的保湿作用能达到有效地抑制皮肤起皱的作用,从而延缓皮肤衰老。
通过下列实施例,将对本发明作更详细的说明。以下的实施例仅仅是说明本发明,应当理解为本发明不仅限于这些实施例。
(1)维生素E卤代乙酸酯的合成
实施例1 维生素E氯代乙酸酯的合成
把10g(23.2mmol)的合成维生素E(dι-α-维生素E)与4.0g(39.4mmol)的三乙胺溶于70ml氯仿中,在冰浴和搅拌下,向该混合物中滴加5.14g(30.0mmol)的氯乙酸酐。加完后,在室温下反应4小时,之后,反应液顺序以50ml水,100ml的5%NaHCO3溶液和50ml水洗涤。洗完后,混合物用Na2SO4干燥,然后减压蒸馏,得到9.5g维生素E氯代乙酸酯(产率:84.0%)。
实施例2 维生素E溴代乙酸酯的合成
把10g(23.2mmol)的合成维生素E(dι-α维生素E)和3.0g(29.7mmol)的三乙胺溶于60ml氯仿中,在冰浴和搅拌下,向该混和物中滴加4.5g(28,7mmol)的溴代乙酰氯。加完后,在室温下反应3小时。之后,反应液顺序以100ml水,70ml的5%NaHCO3溶液和100ml水洗涤。洗完后,混和物用Na2SO4干燥,然后减压蒸馏,得到11.5g维生素E溴代乙酸酯(产率:89.8%)。
实施例3 多乙氧基化的维生素E氯代乙酸酯的合成
把10g(11.5mmol)的多乙氧基化的维生素E(n=10)和3.5g(34.6mmol)的三乙胺溶于60ml氯仿中,在搅拌和冰浴下,向混合物中滴加5.0g(29.2mmol)的氯代乙酸酐。加完后,在室温下反应4小时,之后,反应液顺序以110mol水,70ml的5%NaHCO3溶液和110ml水洗涤。洗涤后,混合物用Na2SO4干燥,然后减压蒸馏,得到11.2g多乙氧基化的维生素E氯代乙酸酯(产率:92.0%)。
(2)非离子维生素E衍生物的合成
实施例4
将20.0g(21.1mmol)按照实施例3制备的多乙氧基化的维生素E氯代乙酸酯(n=10)和6.5g(41.3mmol)的2-(二甲基氨基)乙基甲基丙烯酸酯溶于无水二甲基甲酰胺中,然后在150℃下加热回流24小时,将产生的悬浮液在真空下加热以除去溶剂,用环己烷-乙酸乙酯混合溶在硅胶柱上纯化,得到17.9g的式(I)的非离子维生素E衍生物(产率:80.5%)。产物结构用1H NMR和IR鉴定。1H NMR(CDCl3):δ(ppm),6.10-5.54(s,2H),4.42-3.61(m,42H),3.40(s,2H),2.94-,2.88(t,2H),2.56(s,3H),2.47(s,3H),2.15(s,3H),2.11(s,3H),1.90-1.50(m,2H),1.3-0.95(m,21H),0.67-0.59(m,12H)IR(KBr):2927(-C-H),1759(-C=O),1638(-C=C-),1158(-C-O-)cm-1。
实施例5
10.0g(19.6mmol)的实施例1中制备的维生素E氯代乙酸酯和5.6g(29.2mmol)的2-(二甲基氨基)乙基甲基丙烯酸酯溶于无水四氢呋喃中,在125℃下加热回流48小时,产生的悬浮液在真空下加热除去溶剂,以环己烷-乙酸乙酯硅胶柱纯化,得到7.8g式( Ⅰ)的非离子维生素E衍生物(产率:66.1%)。
实施例6
沿用实施例5中描述的方法,使用实施例2中制备的维生素E溴代乙酸酯,代替维生素E氯代乙酸酯,得到式(Ⅰ)的非离子的维生素E衍生物(产率:71.6%)。
实施例7
沿用实施例5描述的方法,使用多乙氧基化的维生素E氯代乙酸酯(n=20)代替维生素E氯代乙酸酯,得到式(Ⅰ)的非离子的维生素E衍生物(产率:76.2%)。
实施例8
把10.0g(19.6mmol)实施例1中制备的维生素E氯代乙酸酯和6.2g(39.2mmol)的2-(二甲基氨基)乙基丙烯酸酯溶于无水二甲基甲酰胺中,在170℃下加热回流48小时,真空中加热产生的悬浮液以除去溶剂,然后用环己烷一乙酸乙酯混合溶济在硅胶柱上纯化,得到式(Ⅰ)的非离子维生素E衍生物(产率:78.3%)。
实施例9
沿用实施例8中描述的方法,使用实施例2中制备的维生素E溴代乙酸酯代替维生素E氯代乙酸酯,得到式(Ⅰ)的非离子的维生素E衍生物(产率:45.0%)。
实施例10
沿用实施例8中描述的方法,使用四氢呋喃代替无水二甲酰胺,得到式(Ⅰ)的非离子维生素E衍生物(产率:58.0%)。(3)聚合两亲水泡液的合成
实施例11 在水中聚合的聚合两亲水泡液
散于50ml去离子水中,然后于65℃,搅拌下,在有4mg的过硫酸钾(K2S2O8)存在下进行聚合,得到包含有维生素E的聚合两亲的水泡液,该聚合在氮气气氛下进行以避免氧化作用。
聚合反应进行得非常慢被认为是由憎水基团很大从而导致弱的亲水性。
形成的聚合两亲水泡液用显微照像和TEM(JEOL,TEM-100cx)观察。结果是水泡具有封闭的椭圆形状,其短径为300-1,200埃,长径为600-2,300埃。
实施例12 在乙醇中聚合的聚合两亲水泡液
把0.2g实施例5中制备的非离子维生素E衍生物用超声波方法分散于50ml的4%乙醇溶液中,然后在2mg偶氮异丁腈(AIBN)存在下进行聚合反应。该聚合反应在加热到80℃下并且在氮气气氛下进行以避免发生氧化作用。形成的聚合两亲水泡液得到1H-NMR,13C-NMR(CDCl3)和IR的证实。1H NMR(CDCl3):δ(ppm),6.10-5.54(s,2H),4.33-4.27(t,2H),3.67(s,2H),3.02-2.96(t,2H),2.56(s,6H),2.15(s,3H),2.11(s,3H),2.0(s,3H),1.90-1.50(m,2H),1.3-0.95(m,21H),0.67-0.59(m,12H)13C-NMR(CDCl3):δ169.6,167.3(-C=O-),δ149.5(-C=),δ125.6(=CH2),δ75.1,62.9,58.2,55.0(氧化六元环),δ140.2,136.2,126.5,124.8,123.1,117.4(苯),δ75.1,62.9,58.2,55.0(环氧乙烷环α碳,N-CH2-(=O)-),-N-CH2-CH2-O-),δ2.5,29.4,37.6,37.5,37.4,37.3,32.8,32.7,31.0,27.9,24.8,24.5,22.7,22.6,21.0,20.6,19.8,19.7,19.6,19.5,19.3,13.1,12.2,11.8IR(KBr):2927(-C-H),1759(-C=O),1638(-C=C-),1158(-C-O-)。〈试验例〉对热稳定性
实施例11和12中制备的聚合两亲水泡液室温下可保持稳定达8个月或以上。而且,经加热处理到45℃的水泡液可在室温下保持稳定达3个月或以上的时间。〈试验例2〉抗氧化活性
实施例4和5中制备的非离子维生素E衍生物和实施例11和12中制备的聚合两亲水泡液的抗氧化作用按照下述两种方法评价,为了比较活性,也对维生素E、维生素E乙酸酯、大豆卵磷脂和二棕榈基磷脂酰胆碱作了试验。〈试验例2-1〉用DPPH测定的抗氧化作用活性
已知二苯基-2,4,6-三硝基苯基偕腙肼(DDPH)作为自由基反应抑制剂,它因自由基反应而稳定化,而且,它也具有有抗氧化作用活性的化合物所具有的发色特性。因此,本试验利用了上述特性。
把大约50ml DPPH放入试管中,把样品滴加进去。加完后,试管在37℃的恒温浴中保持30分钟,用紫外光谱仪测量颜色变化的程度,结果如表1所示。〈试验例2-2〉用亚油酸测定的抗氧化作用活性
亚油酸由于其中所含的双键很容易氧化为过氧化物,因此,本试验利用了上述特性。
本试验中用的对照溶液通过把2.88ml亚油酸的2.5%的乙醇溶液和9ml和40mmol的磷酸缓冲液(pH 7.0)加入到120ml乙醇中而制得,该对照溶液在暗处40℃下保存。
样品溶液是通过把9.7ml 75%乙醇,0.1ml的30%硫氰酸铵和0.1ml样品加入0.1ml对照溶液中而制得。
3分钟后,用紫外光谱仪在50nm处测量吸收值。低的吸收值意味高的抗氧化作用活性,结果如表1所示。
*对试验例2-1,对照是DPPH溶液,不含样品。
如表一所示,本发明的维生素E衍生物表现了与维生素相似的抗氧化作用活性,其聚合两亲水泡液也表现了稍低于维生素E但高于对照的抗氧化作用活性。
Claims (6)
3.一种制备权利要求1所述的非离子维生素E或多乙氧基化的维生素E衍生物的方法,其特征在于:它包括下列步骤:
(a)使下式(Ⅳ)所代表的维生素E或多乙氧基化的维生素E衍生物与卤代乙酸或卤代乙酸酐反应,生成下式(Ⅴ)所代表的维生素E卤代乙酸酯或多乙氧基化的维生素E卤代乙酸酯衍生物;和 其中,B,n和m的定义如权利要求1;A为-CH2CH(CH3)-或 ;和X为F,Cl,Br或I;
4.权利要求3中所述的方法,其中所说的维生素E选自合成维生素E和天然维生素E;
5.权利要求4中所述的方法,其中所述的合成维生素E选自dι-α维生素E,dι-β维生素E,dι-γ维生素E和dι-δ维生素E。
6.权利要求3中所述的方法,其中步骤(b)中所说的非质子性溶剂选自二噁烷,二甲基甲酰胺和四氢呋喃。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019970032412A KR100195291B1 (ko) | 1997-07-12 | 1997-07-12 | 비이온성 비타민 |
KR32412/1997 | 1997-07-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1205333A true CN1205333A (zh) | 1999-01-20 |
CN1083449C CN1083449C (zh) | 2002-04-24 |
Family
ID=19514258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97119987A Expired - Fee Related CN1083449C (zh) | 1997-07-12 | 1997-10-30 | 非离子维生素e衍生物、其制法和用其制备的聚合两亲水泡液 |
Country Status (6)
Country | Link |
---|---|
US (1) | US5869703A (zh) |
JP (1) | JP3061601B2 (zh) |
KR (1) | KR100195291B1 (zh) |
CN (1) | CN1083449C (zh) |
DE (1) | DE19747600C2 (zh) |
FR (1) | FR2765873B1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI991634A (fi) * | 1999-07-21 | 2001-01-22 | Valtion Teknillinen | Komonomeeri ja sillä polymerointivaiheessa stabiloitu polymeeri |
US7144919B1 (en) * | 2000-08-23 | 2006-12-05 | Youngdae Kim | Polyoxyethylene-polyoxypropylene vitamin E and process for preparation thereof |
FR2822834B1 (fr) * | 2001-04-02 | 2005-02-25 | Flamel Tech Sa | Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation |
KR100533304B1 (ko) * | 2001-05-26 | 2005-12-05 | 주식회사 엘지생명과학 | 폴리에톡실화 알파 토코페롤 에스테르 유도체 및 이의제조방법 |
FR2840614B1 (fr) * | 2002-06-07 | 2004-08-27 | Flamel Tech Sa | Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques |
FR2843117B1 (fr) * | 2002-07-30 | 2004-10-15 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques |
FR2855521B1 (fr) * | 2003-05-28 | 2005-08-05 | Flamel Tech Sa | Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques. |
FR2860516B1 (fr) * | 2003-10-03 | 2006-01-13 | Flamel Tech Sa | Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques |
FR2862536B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
FR2862541B1 (fr) * | 2003-11-21 | 2007-04-20 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interferons et leurs applications therapeutiques |
FR2862535B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee d'interleukines et leurs applications therapeutiques |
US20060165769A1 (en) * | 2004-09-30 | 2006-07-27 | Hyatt John A | Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations |
JP2008156326A (ja) | 2006-12-26 | 2008-07-10 | Shiseido Co Ltd | 化粧料 |
CA2719658C (en) * | 2008-04-01 | 2019-10-01 | Antipodean Pharmaceuticals, Inc. | Compositions and methods for skin care |
FR2952936B1 (fr) * | 2009-11-26 | 2011-11-25 | Flamel Tech | Polymere de type acrylique ou methacrylique comprenant des greffons alpha-tocopherol |
ES2433248B1 (es) * | 2012-05-07 | 2015-03-10 | Consejo Superior Investigacion | Copolimeros anfifilicos portadores de alfa-tocoferol con propiedades antitumorales |
JP6286646B2 (ja) * | 2014-08-25 | 2018-03-07 | 株式会社 Ito Reserch | 新規化合物及びその配合組成物 |
KR101821783B1 (ko) * | 2015-07-10 | 2018-01-24 | 우종원 | 악취방지용 음식물 진공 쓰레기통 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR940010888B1 (ko) * | 1991-03-29 | 1994-11-19 | 주식회사 태평양 | 폴리에톡실레이티드 비타민 e 및 그의 제조방법 |
DE4304303C2 (de) * | 1993-01-22 | 1997-01-30 | Pacific Corp | Vitamin-E-Derivate mit einem quartären Stickstoffatom, Verfahren zu deren Herstellung und kosmetische Mittel enthaltend dieselben |
CA2148148A1 (en) * | 1994-05-20 | 1995-11-21 | Kazumi Ogata | Tocopherol derivatives |
-
1997
- 1997-07-12 KR KR1019970032412A patent/KR100195291B1/ko not_active IP Right Cessation
- 1997-10-28 US US08/959,468 patent/US5869703A/en not_active Expired - Lifetime
- 1997-10-28 DE DE19747600A patent/DE19747600C2/de not_active Expired - Fee Related
- 1997-10-28 JP JP9295644A patent/JP3061601B2/ja not_active Expired - Fee Related
- 1997-10-29 FR FR9713564A patent/FR2765873B1/fr not_active Expired - Fee Related
- 1997-10-30 CN CN97119987A patent/CN1083449C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US5869703A (en) | 1999-02-09 |
KR19990009864A (ko) | 1999-02-05 |
CN1083449C (zh) | 2002-04-24 |
JPH1135577A (ja) | 1999-02-09 |
JP3061601B2 (ja) | 2000-07-10 |
DE19747600A1 (de) | 1999-01-14 |
FR2765873B1 (fr) | 2000-01-14 |
KR100195291B1 (ko) | 1999-06-15 |
DE19747600C2 (de) | 2001-07-26 |
FR2765873A1 (fr) | 1999-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1205333A (zh) | 非离子维生素e衍生物、其制法和用其制备的聚合两亲水泡液 | |
CN1037347C (zh) | 制备聚乙氧基维生素e的方法 | |
CN1260294C (zh) | pH敏感的可生物降解的聚乳酸衍生物形成的聚合物胶束及其在不良水溶性药物传输上的应用 | |
JP4422018B2 (ja) | ミセルアセンブリ | |
LU85952A1 (fr) | Nouveaux composes hemiacetaliques et leurs applications | |
CN101050243A (zh) | 一种两亲性壳聚糖衍生物及其制备方法和在药剂学中的应用 | |
WO2000066635A1 (fr) | Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes | |
EP1819824A1 (fr) | Composes analogues de lipides membranaires d'archaebacteries et compositions liposomiales integrant de tels composes | |
WO2023179463A1 (zh) | 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统 | |
JP3860246B2 (ja) | 陽イオン性ビタミンe誘導体及びその製造方法、並びにこれを用いて形成した両親媒性高分子 | |
JP5446119B2 (ja) | 低級アシル基含有ポリアミドアミンデンドロン脂質 | |
CN110305301B (zh) | 一种两亲性的树枝化含糖共聚物及其合成方法 | |
JP3498339B2 (ja) | リン脂質誘導体 | |
CN106562929A (zh) | 一种制备新颖脂质体包裹自旋靶向药用化合物l‑mpbn纳米粒的方法 | |
JPH07242680A (ja) | 反応性小胞体、形成剤および機能性物質固定化小胞体 | |
RU2823298C1 (ru) | Ионизируемые катионные липиды для доставки нуклеиновых кислот | |
KR0162283B1 (ko) | 비이온성 비타민 e 유도체 및 그의 제조방법, 및 그를 이용하여 형성한 항산화작용을 갖는 양친매성 고분자 베시클 | |
JP3590983B2 (ja) | リン脂質誘導体 | |
CN117003807A (zh) | 一种结构脂质化合物及其制备方法和用途 | |
JP3498336B2 (ja) | リン脂質誘導体 | |
JP3303481B2 (ja) | 反応性小胞体および形成剤 | |
CN118750465A (zh) | 一种含氟脂质纳米颗粒的制备方法及应用 | |
JP3130135B2 (ja) | リン脂質小胞体用安定化剤 | |
JP3575037B2 (ja) | 反応性小胞体および形成剤 | |
Wathier et al. | Stabilization of polymerized vesicular systems: an application of the dynamic molecular shape concept |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |